Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.
Financial Results:
Granules India Ltd reported Revenues for Q2FY24 of ₹1,189.00 Crores up from ₹1,151.00 Crore year on year, a rise of 3.3%.
Total Expenses for Q2FY24 of ₹1,056.00 Crores up from ₹965.00 Crores year on year, a rise of 9.43%.
Consolidated Net Profit of ₹102.00 Crores down 29.66% from ₹145.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹4.21, down 27.91% from ₹5.84 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.